Medical devices, healthcare technology and the business of care
510(k) clearance · K261447

CVAC Aspiration System

Calyxo, Inc. · Decision date Sep 15, 2026

MEDTECHLEDGER EXPLANATIONK261447

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 15, 2026 for K261447, the CVAC® Aspiration System submitted by Calyxo, Inc. of Pleasanton, California. The device is a sterile, single-use steerable ureteral catheter with irrigation and vacuum functionality, used with the reusable CVAC Image Processor; it is classified under 21 CFR 876.1500, Class II, product code FGB, in the Gastroenterology/Urology panel. A 510(k) clearance is not a PMA approval.

The submission identifies the predicate as the CVAC Aspiration System within the CVAC Set cleared under K233472, with the CVAC Image Processor (K260013) as reference device. The summary describes changes to the passive-mode outflow path and handle component geometry, labeled CVAC 2.1, while dimensions, navigation, camera tip, accessories, single-use status, EtO sterilization and one-year shelf life are listed as unchanged. Software, cybersecurity, sterilization, shelf life, electrical safety and EMC data were leveraged. The record does not include clinical outcome data, and the public page lists a May 1, 2026 receipt date while the summary letter states August 21, 2026.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 15, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261447
Regulatory pathway
510(k) premarket notification
Applicant
Calyxo, Inc.
Product code
FGB
Decision code
SESE
Decision date
Sep 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ureteroscope And Accessories, Flexible/Rigid.

Applicant
Calyxo, Inc.
Product code
FGB
FDA device class
2

FDA decision timeline

  1. K261447 received

    Application receipt date recorded by FDA.

  2. K261447 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code FGB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Calyxo, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Pleasanton, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records